Go to the list of all blogs
Allana's Avatar
published in Blogs
Oct 25, 2026
TickeronGET DAILY SIGNALS
XLV Health Care ETF Delivers +6% Gain as Pharma Leaders Lead Recovery

XLV Health Care ETF Delivers +6% Gain as Pharma Leaders Lead Recovery

Key Takeaways

  • XLV tracks the Health Care Select Sector Index, holding roughly 60-plus S&P 500 health care companies at a low 0.08% expense ratio.
  • The portfolio is highly concentrated, with Eli Lilly, Johnson & Johnson, and AbbVie representing close to one-third of assets.
  • Over the most recent 30-day period, the fund rose approximately 6%, reflecting renewed pharmaceutical and biotechnology leadership.
  • Health care blends defensive, recession-resistant demand with growth themes such as GLP-1 obesity treatments and biotech innovation.
  • Principal risks include drug-pricing policy, regulatory shifts, and heavy reliance on a handful of mega-cap names.
  • For additional perspective on this fund, explore Price Targets and Forecast pages dedicated to XLV.
  • Investors seeking systematic ideas can also explore Trending AI Robots for AI-driven trading strategies.

Understanding the XLV ETF Structure

The Health Care Select Sector SPDR Fund is a passively managed exchange-traded fund that seeks to match, before fees and expenses, the price and yield performance of the Health Care Select Sector Index. That benchmark includes the health care constituents of the S&P 500, spanning pharmaceuticals, biotechnology, health care equipment and supplies, health care providers and services, and life sciences tools and services. The fund employs a replication strategy, generally investing substantially all of its assets in the underlying index securities.

XLV holds approximately 60 to 64 positions, with assets under management in the low-to-mid $40 billion range, making it one of the largest health care sector ETFs. Its expense ratio is 0.08%, among the lowest in the category. The portfolio is top-heavy: Eli Lilly is the largest holding at roughly 15% of assets, followed by Johnson & Johnson near 10% and AbbVie around 7% to 8%. Other sizable positions include Merck, UnitedHealth Group, Thermo Fisher Scientific, Amgen, Gilead Sciences, and Abbott Laboratories. This concentration means a sharp move in any single mega-cap name can meaningfully sway overall fund returns. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Broader Health Care Themes and Drivers

The broader health care environment reflects a mix of defensive characteristics and structural growth drivers. Demand for medical services, pharmaceuticals, and devices tends to remain relatively stable across economic cycles, which can make the sector attractive during periods of macroeconomic uncertainty. At the same time, innovation in areas such as GLP-1 obesity and diabetes therapies, immunology, oncology, and surgical robotics has supported earnings growth and investor interest in several of the sector's largest companies.

Monetary policy and interest rates also influence the sector. Health care equities, particularly large, cash-generative pharmaceutical and managed-care names, are often viewed as defensive relative to more cyclically sensitive industries. Inflation, drug-pricing legislation, and evolving regulatory frameworks in the United States remain important watchpoints, while capital flows into and out of sector ETFs reflect shifting investor sentiment on growth versus value positioning.

Recent Performance and Positioning

In recent weeks, XLV showed a pattern of gradual weakness followed by a sharp recovery. After trading in the low $170s in late August, the fund pulled back toward the mid-$160s in late September and early October before rallying back above $179 by late October. Over the most recent 30-day period, this translated to an advance of roughly 6%, a move that remained range-bound rather than volatile in nature.

The rebound was led disproportionately by the portfolio's largest pharmaceutical positions. Eli Lilly has posted a strong multi-month advance tied to continued momentum in its obesity and diabetes franchise, while Merck and Johnson & Johnson have also contributed meaningfully. With the top ten holdings accounting for well over half of the fund's assets, concentration has amplified the influence of these names on sector-level performance. Broader sector rotation toward defensives and health care innovation themes reinforced the move. From what I see, this concentration is worth monitoring closely.

Key Factors Shaping the 2026 Outlook

Several structural factors are likely to shape XLV during 2026. The earnings cycles of its largest pharmaceutical and biotech holdings will remain central, particularly continued demand for GLP-1 therapies and the commercial progress of immunology and oncology pipelines. Interest-rate expectations and the broader inflation backdrop will influence the relative appeal of defensive health care equities against other sectors, while any changes to U.S. drug-pricing or health care policy could alter the profit outlook for managed-care and pharmaceutical companies.

Capital flows into health care ETFs, merger-and-acquisition activity, and the pace of biotech innovation represent additional variables. Because the fund is concentrated in a limited number of mega-cap names, company-specific developments and regulatory decisions may carry outsized influence. Monitoring sector rotation, portfolio holdings, and the macroeconomic environment will be essential for investors assessing how the fund's positioning evolves over the coming months.

Using Tickeron Tools for Deeper Analysis

In my own research process, I often turn to Tickeron’s AI-powered platforms to cross-check sector trends and identify comparable opportunities. The AI Screener stands out for its ability to scan thousands of securities with technical indicators, fundamentals, volatility measures, AI-generated signals, market trends, price patterns, and customizable filters. It surfaces trending securities and breakout candidates efficiently, helping compare health care exposure against other sectors without replacing independent judgment. This approach adds a structured layer to evaluating funds like XLV alongside broader market dynamics.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: XLV

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


XLV in -2.17% downward trend, falling for three consecutive days on November 20, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where XLV declined for three days, in 250 of 308 cases, the price declined further within the following month. The odds of a continued downward trend are 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for XLV moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 27 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XLV as a result. In 72 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.

The Moving Average Convergence Divergence Histogram (MACD) for XLV turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 38 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The 10-day moving average for XLV crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.

Following a +0.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where XLV advanced for three days, in 264 of 325 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

XLV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 225 of 273 cases where XLV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Unitedhealth Group (NYSE:UNH), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Abbott Laboratories (NYSE:ABT), Pfizer (NYSE:PFE), Intuitive Surgical (NASDAQ:ISRG).

Industry description

The investment seeks investment results that, before expenses, correspond generally to the price and yield performance of publicly traded equity securities of companies in the Health Care Select Sector Index. In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.

Market Cap

The average market capitalization across the State Street Health Care Select Sector SPDR ETF (XLV) ETF is 115.33B. The market cap for tickers in the group ranges from 9.59B to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is HSIC at 9.59B.

High and low price notable news

The average weekly price growth across all stocks in the State Street Health Care Select Sector SPDR ETF (XLV) ETF was -6%. For the same ETF, the average monthly price growth was -1%, and the average quarterly price growth was 19%. SYK experienced the highest price growth at 0%, while UNH experienced the biggest fall at -17%.

Volume

The average weekly volume growth across all stocks in the State Street Health Care Select Sector SPDR ETF (XLV) ETF was 61%. For the same stocks of the ETF, the average monthly volume growth was 18% and the average quarterly volume growth was 26%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 64
P/E Growth Rating: 46
Price Growth Rating: 35
SMR Rating: 59
Profit Risk Rating: 70
Seasonality Score: 33 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
SSO is a 2x daily leveraged ETF (exchange-traded fund) that seeks double the daily return of the S&P 500, while XXX is a non-leveraged, passive fund blending roughly 75% S&P 500 exposure with 25% XRP, a major cryptocurrency. Both funds charge comparable fees — about 0.87% for SSO and roughly 0.85% for XXX — but their risk profiles are fundamentally different.
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.